Barclays’s Charles River Laboratories CRL Stock Holding History

Barclays’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,000	Closed	-$980K	–	5239
2023 Q3	$980K	Buy	+5,000	New	+$1.03M	﹤0.01%	2355
2014 Q3	–	Sell	-100	Closed	-$5K	–	7670
2014 Q2	$5K	Hold	100	–	–	﹤0.01%	7107
2014 Q1	$6K	Buy	+100	New	+$5.83K	﹤0.01%	7128
2013 Q4	–	Sell	-50,000	Closed	-$2.3M	–	7545
2013 Q3	$2.3M	Buy	+50,000	New	+$2.29M	﹤0.01%	2413

Other funds holding CRL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Barclays's CRL Position: Q3 2026 in Review

Barclays reduced its Charles River Laboratories (CRL) stake by 7.9% in Q3 2026, selling an estimated $1.12M and leaving 49,631 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

Barclays first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.5M in Q1 2026. 287 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Barclays held 49,631 shares of Charles River Laboratories worth $14.6M as of Q3 2026.
Barclays sold 4,265 Charles River Laboratories shares in Q3 2026, an estimated $1.12M.
Charles River Laboratories made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1418 holding.
Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
Barclays's Charles River Laboratories position peaked at $40.5M in Q1 2026.
287 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.